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Objective. To investigate the endocrine and/or clinical characteristics of women with low anti-Mu¨llerian hormone (AMH) that
could improve the accuracy of IVF outcome prediction based on the female age alone prior to the first GnRH antagonist IVF
cycle. Methods. Medical records of 129 patients with low AMH level (<6.5 pmol/L) who underwent their first GnRH antagonist
ovarian stimulation protocol for IVF/ICSI were retrospectively analyzed. The main outcome measure was the area under the
ROC curve (AUC-ROC) for the models combining age and other potential predictive factors for the clinical pregnancy. Results.
Clinical pregnancy rate (CPR) per initiated cycles was 11.6%. For the prediction of clinical pregnancy, DHEAS and age showed
AUC-ROC of 0.726 (95%CI 0.641–0.801) and 0.662 (95%CI 0.573–0.743), respectively (𝑃 = 0.522). The predictive accuracy of the
model combining age and DHEAS (AUC-ROC 0.796; 95%CI 0.716–0.862) was significantly higher compared to that of age alone
(𝑃 = 0.013). In patients <37.5 years with DHEAS > 5.7 pmol/L, 60% (9/15) of all pregnancies were achieved with CPR of 37.5%.
Conclusions. DHEAS appears to be predictive for clinical pregnancy in younger women (<37.5 years) with low AMH after the
first GnRH antagonist IVF cycle. Therefore, DHEAS-age model could refine the pretreatment counseling on pregnancy prospects
following IVF.
1. Introduction
Counseling infertile couples about chances of IVF success
is one of the most demanding clinician’s tasks. Since the
number of oocytes retrieved and fertilized is found to be of
the highest predictive value in pregnancy prediction models
based on intermediate results of IVF treatment, patients in
whom low number of oocytes were retrieved after controlled
ovarian stimulation for IVF could generally considered as
having poor pregnancy prospects [1–4]. Obviously, data on
previous ovarian stimulations are not available before the
first IVF cycle, so clinician should be able firstly to identify
the patients at risk of poor response in order to optimize the
stimulation dose regimen and secondly to counsel them on
probability of pregnancy as accurately as possible by using
baseline patient characteristics.
Serum anti-Mu¨llerian hormone (AMH) level is consid-
ered to be a valuable quantitative marker of ovarian reserve
[5–8]. It is predictive of poor response to ovarian stimulation
with exogenous gonadotrophins, but there is no convincing
evidence supporting the value of AMH measurement in
predicting pregnancy and live birth after IVF yet [7, 9–
11]. However, protocols with dose adjustment according to
AMH were demonstrated to improve ovarian response and
treatment outcome [3, 12].
Female age is the most important patient characteristic in
determining prospects of IVF success [1], although value of
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age as a single predictor of pregnancy was not found to be
optimal [7].
Themodel combiningAMHand agewas recently demon-
strated as having the moderate value in prediction of live
birth after IVF suggesting that in lowAMHcategory, younger
women aremore likely to become pregnant then womenwith
advanced age [10].
Other investigated patient characteristics either failed to
demonstrate any added value to female age in predicting
pregnancy after IVF or their values were not clearly estab-
lished yet [4, 7].
The rationale for this study was to improve the prediction
of pregnancy chances at initial IVF counseling in patients
expected to poorly respond on ovarian stimulation based on
their AMH levels, since poor responders are not homoge-
neous group regarding the pregnancy prospects [4].
Accordingly, the objectives of this study were firstly to
determine whether any of investigated clinical and biochem-
ical characteristic(s) add(s) value to female age in predicting
clinical pregnancy prior to the firstGnRHantagonist protocol
of ovarian stimulation for IVF/ICSI in patients with low
AMH values (<6.5 pmol/L), and secondly to develop an easy-
to-use counseling approach that would more accurately than
the model based on female age alone differentiate patients
with low AMH who show favorable prognosis for pregnancy
from those with little chances for treatment success.
2. Materials and Methods
2.1. Study Population. In this study, medical records on
IVF treatments and laboratory test results derived from the
electronic database in Department of Human Reproduction
ofMerkur TeachingHospital (Zagreb, Croatia) were analyzed
retrospectively. All data were prospectively collected and
recorded by authorized staff of the department between
October 2010 and February 2012. The IVF cycles included in
the analysis met all of the following criteria: (1) null gravidity,
(2) normal uterus and uterine cavity, (3) no history of pelvic
disease or surgery, (4) no history of the use of medications
that could interfere with basal hormone status, (5) sperm
count of, at least, 1 × 106/mL, (6) first IVF/ICSI cycle,
(7) AMH and other laboratory tests values obtained within
three months preceding controlled ovarian stimulation, (8)
serum AMH concentration <6.5 pmol/L, (9) a fixed dose
of 300 I.U. hMG administered daily from the day 3 in the
GnRHantagonist protocol of ovarian stimulationwith an oral
contraceptive (OC) pretreatment.
It has been previously demonstrated that serum AMH
concentrations <5 pmol/L identify women who demonstrate
poor ovarian response and reduced clinical pregnancy rate
(CPR) independent of treatment strategy and age [3, 6].
This cut-off value was determined using DSL MIS/AMH
ELISA (reference DSL-10-14400; DSL, Webster, USA). In our
laboratory serum AMH concentrations were measured using
AMH Gen II ELISA (Beckman Coulter, Inc, Brea, USA).
Although method comparison has shown a good agreement
between the results obtained usingDSLAMH/MIS andAMH
Gen II, the serum AMH values obtained by the AMH Gen II
assay were approximately 40% higher [13]. Therefore, in the
present study, the AMH threshold value for the poor ovarian
response was arbitrarily set at the higher level (6.5 pmol/L).
All IVF patients gave an informed consent at initial
consultation for their data to be used for clinical research,
statistical reports, and/or educational purposes provided that
their identity remains protected. This study was approved by
the institutional Ethics Committee.
2.2. Stimulation Protocol. A standard GnRH antagonist pro-
tocol was used for controlled ovarian stimulation. After OC
pretreatment for 21–30 days, which was used for scheduling
purposes, ovarian stimulation was commenced on cycle day
3 with a daily dose of 300 I.U. of hMG (Menopur; Ferring
GmbH, Kiel, Germany) subcutaneously for five days, if the
presence of ovarian cysts was excluded by TV-US. According
to routine clinical practice, follicular responses were moni-
toredwith serum𝐸
2
measurements and by transvaginal ultra-
sonography (TV-US) to assess the follicular growth and to
define proper timing for triggering final oocyte maturation.
On the cycle day 8, the TV-US was performed and the
𝐸
2
concentration was determined. If significant increase in
𝐸
2
concentration occurred and at least one follicle >11mm
in diameter was visualized on TV-US, the stimulation was
continued at the same hMG dose, and administration of
the GnRH antagonist (Cetrotide; Baxter Oncology GmbH,
Frankfurt, Germany) was started at a daily dose of 0.25mg
(subcutaneously) to be continued until the morning of the
day of hCG administration. Alternatively, the stimulation
was cancelled. Final oocyte maturation was induced with
10 000 I.U. of hCG (Brevactid 5000 I.E., Ferring GmbH, Kiel,
Germany), i.m., when at least one follicle >17mm in diameter
was present on TV-US. Oocytes were retrieved 36 hours after
hCGadministration byTV-US guided aspiration. All patients
in whom the oocytes were retrieved received 1500 I.U. of
hCG for luteal phase support on the day of oocyte retrieval.
Fertilization of oocytes was performed by IVF or ICSI in
compliance with Croatian law regulating medically assisted
reproduction. This law was in force from September 2009
until July 2012 and imposed that no more than three oocytes
can be fertilized at one time and all embryos obtained must
be transferred simultaneously. Accordingly, if ≥3 oocytes
were retrieved, 3 oocytes were selected for fertilization by
standard procedure and the remaining good-quality oocytes
were frozen. All embryos obtained were transferred under
ultrasonographic guidance two or three days after oocyte
retrieval. Luteal phase support with progesterone capsules
(Utrogestan 100mg; Laboratories Besins International, Mon-
trouge, France), 200mg three times a day, was given intrav-
aginally from the day of oocyte retrieval until the day of
serum hCG determination (18 ± 1 day after oocyte retrieval).
If pregnancy was confirmed by determination of serum hCG,
luteal phase support with Utrogestan 200mg continued until
12 weeks of gestational age. Clinical pregnancywas confirmed
if fetal cardiac activity was observed at TV-US 28±1 day after
oocyte retrieval.
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2.3. Laboratory Analysis. Blood samples for the hormone
measurements were taken during the early follicular phase
of menstrual cycle (i.e., cycle days 3–5 of a spontaneous
menstrual cycle or a withdrawal bleeding induced by 100mg
ofmicronized progesterone vaginally tid for 10 days) between
8:00 and 10:00 hours after an overnight fast. Serum concen-
trations of DHEAS, 𝐸
2
, FSH, hCG, LH, PRL and T were
determined by chemiluminescent immunoassays (Beckman
Coulter, Inc., Fullerton, USA).The limit of detection, within-
and between-assay coefficients of variation (CVs) were as
follows: 0.05𝜇mol/L, 2.5% and 2.1% for DHEAS; 73 pmol/L,
6.0% and 3.4% for 𝐸
2
; 0.2 IU/L, 2.9% and 3.4% for FSH;
0.5 IU/L, 1.6% and 2.6% for hCG; 0.2 IU/L, 4.2% and 2.7%
for LH; 5.3mIU/L, 1.9% and 1.1% for PRL, 0.35 nmol/L,
3.6% and 2.3% for T. TSH concentration was measured by
using theADVIACentaur XP immunoassay system (Siemens
Healthcare Diagnostics, Inc., Tarrytown, USA). The limit of
detection, within- and between-assay CVs were 0.001mIU/L,
2% and 4% for TSH. The total precision of the DHEAS,
𝐸
2
, FSH, hCG, LH, PRL, T, and TSH measurements was
as follows: 3%, 6%, 3.9%, 4.2, 5%, 2.4%, 3.8%, and 3.2%
(calculated by using guidelines described in CLSI document
EP15-A2) [14]. Serum AMH concentration was determined
using AMH Gen II ELISA (Beckman Coulter, Inc., Brea,
USA). For AMH, the limit of quantification is 1.14 pmol/L
and the limit of detection is 0.56 pmol/L as specified by the
manufacturer. Within- and between-assay CVs were 2.5%
and 1.5%, respectively. Total precision demonstrated in our
laboratory was 3.1% [14]. All biochemistry analyses were
performed in the laboratory accredited according to EN ISO
15189.
2.4. Clinical Investigation. Anthropometric measurements
and transvaginal ultrasound scanning were performed the
same day as blood drawing for the hormone analysis.
The number of follicles measuring 2–9mm in diameter
(AFC) in each ovary was assessed by a single investigator
(M.Sˇ.A.) using a two-dimensional transvaginal probe 5–
7MHz (Toshiba, Nemio, Japan).
2.5. Statistical Methods. Medcalc Software version 12.3.0
(Mariakerke, Belgium) was used for statistical analysis. Base-
line patient characteristics, treatment, and IVF outcomes
data of pregnant and nonpregnant patients were compared
using Mann-Whitney test. Univariate and multivariate logis-
tic regression analyses were used to investigate the potential
association between independent variables (age, body mass
index (BMI), AFC, AMH, DHEAS, 𝐸
2
, FSH, LH, T, PRL,
TSH) and the dependent variable (clinical pregnancy). The
receiver operating characteristic (ROC) curves were plotted
firstly to determine the discriminative power of the tested
variables using area under the receiver operating character-
istic curve (AUC-ROC), and secondly to determine the cut-
off values with the optimal performances for discrimination
between pregnancy and non-pregnancy. The Kruskal-Wallis
test with post-hoc analysis and the Fisher’s exact test were
used for comparison of the IVF outcomes between the groups
stratified using the cut-off values of the variables identi-
fied as predictive of the clinical pregnancy. The AUC-ROC
comparison was used to compare predictive performances
of the multivariate model and the age-alone model. 𝑃 value
of <0.05 was considered as statistically significant. Due to
rigorous inclusion criteria and limited number of events
in the original dataset, developed counseling approach was
internally validated on the 1000 bootstrap replications of
the original sample. The classification and reclassification
of patients according to their pregnancy chances were per-
formed based on the age-alone model and the multivariate
model, respectively, in order to assess the clinical usefulness
of the approach [15].
3. Results
Medical records of 803 IVF cycles were searched using
inclusion criteria and 129 cycles were selected for the statis-
tical analysis. There were 7% (9/129) cancelled cycles, 9.3%
(12/129) cycles in which no oocytes were retrieved, and 19.4%
(25/129) cycles ended by a fertilization failure. In total, 64.3%
(83/129) of initiated cycles were followed by embryo transfer.
Implantation rate (total number of viable embryos× 100/total
number of embryos transferred) was 12.8% (20/156) and
clinical pregnancy rate per initiated cycle (CPR) was 11.6%
(15/129). Two clinical pregnancies were recorded in patients
with AMH concentration below the limit of quantification
(<1.14 pmol/L). When baseline patient characteristics were
compared, statistically significant differences in age and
DHEAS concentration between pregnant and nonpregnant
group were found (𝑃 = 0.043 and 𝑃 = 0.005, resp.). All other
baseline clinical and biochemical characteristics as well as the
treatment data were similar in both groups (Table 1).
The results of univariate and multivariate logistic regres-
sion analysis are shown in Table 2. The univariate logistic
regression analysis revealed DHEAS as the best single pre-
dictor of clinical pregnancy (AUC-ROC0.726, 95% CI 0.641–
0.801). However, when AUC-ROC of DHEAS was compared
to that of the age, as the second best single predictor, the
predictive power of DHEASwas not found to be substantially
and significantly different (𝑃 = 0.522). The predictive
potential for clinical pregnancy of all other tested variables
was not demonstrated.
The cut-off values of 37.5 years for age (odds ratio (OR)
6.7; 95% CI 1.5–31.2) and 5.7𝜇mol/L for DHEAS (OR 7.9;
95% CI 2.5–25.4) were derived from ROC curve analysis
as having optimal performances in discrimination between
pregnancy and non-pregnancy. The subsequent multivari-
ate logistic analysis using DHEAS and age as continu-
ous variables eliminated the age from the model for the
pregnancy prediction. Therefore, the categorical model for
clinical pregnancy prediction based on the cutoffs for age
and DHEAS (DHEAS-age model) was developed. The better
predictive performance of DHEAS-age model compared to
the age-alone model was demonstrated by the AUC-ROC
comparison (Table 2, Figure 1).
In order to internally validate the clinical value of the
DHEAS-age model, the patients were grouped according to
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Table 1: Baseline patient and treatment characteristics of studied IVF cycles resulting in clinical pregnancy and nonpregnancy.
Variable Overall group Nonpregnant Pregnant P valuea
(𝑛 = 129) (𝑛 = 114) (𝑛 = 15)
Age (y) 37.0 ± 3.7 37.3 ± 3.7 35.0 ± 3.6 0.043
BMI (kg/m2) 23.9 ± 3.8 24.0 ± 3.9 23.5 ± 2.0 0.976
AFC 6.6 ± 3.7 6.4 ± 3.6 8.1 ± 4.3 0.134
AMH (pmol/L) 3.0 ± 1.7 3.0 ± 1.7 3.5 ± 1.9 0.246
DHEAS (𝜇mol/L) 4.5 ± 1.9 4.3 ± 1.8 5.9 ± 2.2 0.005
FSH (IU/L) 9.7 ± 6.7 9.8 ± 7.1 9.1 ± 3.2 0.752
LH (IU/L) 4.6 ± 2.2 4.7 ± 2.3 4.5 ± 1.6 0.755
𝐸
2
(pmol/L) 223 ± 123 223 ± 123 224 ± 102 0.823
𝑇 (nmol/L) 1.4 ± 0.7 1.4 ± 0.6 2.3 ± 1.0 0.273
Duration of stimulation (d) 10.3 ± 1.9 10.3 ± 1.9 10.5 ± 0.8 0.688
Total gonadotrophins used (IU) 3095.5 ± 553.6 3089.5 ± 582.4 3140 ± 250.1 0.741
Number of ICSI cycles, % (𝑛/𝑁) 75.0 (81/108) 75.3 (70/93) 73.3 (11/15) 0.540
Note: values are presented asmean± SD. AFC: antral follicle count; AMH: anti-Mu¨llerian hormone; BMI: bodymass index. Conversion formulas for the AMH,
DHEAS, 𝐸2, and 𝑇 values in mass units are as follows: ng/mL = pmol/L: 7.14, 𝜇g/dL × 0.027 = 𝜇mol/L, pg/mL × 3.67 = pmol/L, and ng/dL × 0.0347 = mmol/L.
apregnant versus nonpregnant.
Table 2: Univariate and multivariate logistic regression analysis of variables studied for the prediction of clinical pregnancy in patients with
low AMH and area under the receiver operating characteristic curves (AUC-ROC) analysis.
Variable 𝑅2 𝑃 value AUC-ROC 95% CI
Univariate continuous models
DHEAS 0.466 0.004 0.726 0.641–0.801
Age −0.173 0.031 0.662 0.573–0.743
AFC 0.115 0.104 0.619 0.529–0.703
AMH 0.172 0.260 0.592 0.502–0.678
BMI −0.038 0.626 0.502 0.413–0.592
𝐸
2
0.086 0.969 0.518 0.428–0.607
FSH −0.020 0.661 0.525 0.435–0.614
LH −0.024 0.848 0.525 0.435–0.613
𝑇 0.473 0.234 0.587 0.497–0.673
PRL −0.008 0.843 0.501 0.412–0.590
TSH −0.044 0.747 0.544 0.454–0.632
Univariate categorical model
Age-c −1.907 0.015 0.688 0.600–0.766
Multivariate categorical model
DHEAS-age −1.167 0.001 0.796 0.716–0.862
Note: 𝑅2: regression coefficient; 𝑃: 𝑃 value for 𝑅2; CI: confidence interval; AFC: antral follicle count; AMH: anti-Müllerian hormone; BMI: body mass index;
age-c: univariate categorical model using age as categorical variable with cut-off value of 37.5 years; DHEAS-age: multivariate categorical model using DHEAS
as categorical variable with cut-off value of 5.7𝜇mol/L and age as categorical variable with cut-off value of 37.5 years.
the selected cut-off values for the age and DHEAS (Table 3).
In the <37.5 years age category, DHEAS discriminated well
between pregnancy and non-pregnancy (AUC 0.712; 95% CI
0.591–0.815; 𝑃 = 0.004).
As shown in Table 3, the observed CPR was high in
the <37.5 years and DHEAS > 5.7𝜇mol/L cohort (Group 1,
𝑛 = 24) and significantly different from the CPR of the age-
matched group of patients with DHEAS ≤ 5.7 𝜇mol/L (Group
2, 𝑛 = 45), 37.5% versus 8.9% (𝑃 < 0.05). Furthermore,
60% (9/15) of all pregnancies were achieved in Group 1. The
number of oocytes retrieved and the number of embryos
transferred did not differ between these two groups. Sig-
nificant between-group differences in other baseline patient
characteristics were not found in <37.5 years age category of
the patients, except in T levels.
Within the≥37.5 years age category, patients withDHEAS
> 5.7𝜇mol/L (Group 3, 𝑛 = 9) had higher CPR than patients
with DHEA-S ≤ 5.7 𝜇mol/L (Group 4, 𝑛 = 51). However, the
observed difference did not reached the level of significance.
In this age-category, the data on DHEAS levels did not
provide an additional information regarding the pregnancy
prospects (AUC-ROC 0.681; 𝑃 = 0.471).
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Table 3: Baseline patient characteristics, treatment variables, and IVF outcomes of the patients grouped according to the cut-off values for
female age and DHEAS level predictive of clinical pregnancy (cutoffs are selected by ROC curve analysis).
Age category (years) <37.5 ≥37.5
>5.7 ≤5.7 >5.7 ≤5.7
DHEAS category (𝜇mol/L) Group 1 Group 2 Group 3 Group 4
(𝑛 = 24) (𝑛 = 45) (𝑛 = 9) (𝑛 = 51)
Patient characteristics
Age (y) 34.0 ± 2.7(3)(4) 34.1 ± 1.8(3)(4) 39.7 ± 1.7(1)(2) 40.5 ± 1.9(1)(2)
BMI (kg/m2) 23.5 ± 3.8 23.0 ± 3.3(3)(4) 26.2 ± 5.0(2) 24.5 ± 3.7(2)
AFC 7.0 ± 4.0 7.4 ± 3.6 6.0 ± 3.0 5.8 ± 3.7
AMH (pmol/L) 3.2 ± 1.9 3.5 ± 1.8(4) 2.3 ± 1.5 2.6 ± 1.6(2)
DHEAS (𝜇mol/L) 7.0 ± 0.7(2)(4) 3.6 ± 1.2(1)(3) 6.9 ± 0.9(2)(4) 3.5 ± 1.4(1)(3)
FSH (IU/L) 9.0 ± 2.9 9.6 ± 8.3 9.1 ± 4.1 10.3 ± 6.9
LH (IU/L) 4.3 ± 1.8 4.6 ± 2.6 3.9 ± 1.1 5.0 ± 2.2
𝐸
2
(pmol/L) 192 ± 73 217 ± 103 248 ± 130 239 ± 153
𝑇 (nmol/L) 1.9 ± 0.6(2)(4) 1.2 ± 0.5(1)(3) 2.0 ± 1.9(2)(4) 1.3 ± 0.6(1)(3)
Treatment variables
Duration of stimulation (d) 10.7 ± 1.3 10.3 ± 1.6 10.6 ± 3.0 10.7 ± 1.5
Total gonadotrophins used (IU) 3200 ± 392 2953 ± 643 3167 ± 901 3064 ± 633
Number of ICSI cycles, % (𝑛/𝑁) 73.9 (17/23) 72.2 (26/36) 71.4 (5/7) 76.2 (32/42)
IVF outcomes
Number of oocytes retrieved 3.1 ± 1.4(4) 3.2 ± 2.4(4) 2.9 ± 1.7 2.0 ± 1.5(1)(2)
Number of oocytes eligible for fertilization 2.5 ± 0.8(4) 2.2 ± 1.1(4) 2.1 1.6(1)(2)
Number of embryos transferred 1.5 ± 1.1 1.3 ± 1.2 0.9 ± 1.1 1.0 ± 0.9
Implantation rate per embryo transferred (%) 32.4(2)(4) 8.6(1)(4) 12.5 3.8(1)(2)
Clinical pregnancy rate per cycle initiated (%) 37.5(2)(4) 8.9(1) 11.1 2.0(1)
Note: values are presented as mean ± SD. AFC: antral follicle count; AMH: anti-Mu¨llerian hormone; BMI: bodymass index Conversion formulas for the AMH,
DHEAS, 𝐸2, and 𝑇 values in mass units are as follows: ng/mL = pmol/L: 7.14, 𝜇g/dL × 0.027 = 𝜇mol/L, pg/mL × 3.67 = pmol/L, and ng/dL × 0.0347 = mmol/L,
respectively. Fisher’s exact test, Chi-quadrat test, and Kruskal-Wallis test with post-hoc analysis according to Conover were used for between-group comparison
where appropriate. Superscripted numbers in parentheses denote (1)P< 0.05 compared with Group 1; (2)P< 0.05 compared with Group 2; (3)P< 0.05 compared
with Group 3; (4)P < 0.05 compared with Group 4.
Notably, the significant difference was not found when
CPR in Group 2 was compared with CPR in Group 4 (8.9%
versus 2%; 𝑃 = 0.291). As depicted in Table 3, there was
no substantial difference in CPR between these two groups
despite the significant difference in age, the number of
the oocytes retrieved, and the number oocytes eligible for
fertilization.
The AUC-ROC of the DHEAS-age model after correc-
tion for overoptimism was 0.790 (95% CI 0.710–0.857). The
predicted over observed CPRs in bootstrapped samples were
0.98, 1.03, 1.07, 0.83 for each group, demonstrating a good
calibration of the model.
After DHEAS-age model was applied on the study pop-
ulation, 15% (9/60) of those patients previously classified
by age-alone model as having <5% chance for pregnancy
and 65% (45/69) of those classified as having >20% chance
were reclassified in the new category with the pregnancy
probability of ≈10%.
4. Discussion
It is generally recognized that the poor responders have
lower pregnancy rates than normal responders, regardless of
definition used for the poor response to ovarian stimulation
[4, 16, 17]. In the present study, AMH level (cut-off value of
6.5 pmol/L) was used for identification of the patients at risk
for the poor response.
In overall study population theCPR following the ovarian
stimulation for IVF according to GnRH antagonist protocol
was 11.6%, which is in accordance with previous reports on
reduced pregnancy prospects in women with diminished
ovarian reserve [3, 6, 18].
However, our study results failed to demonstrate the
association between the AMH levels and IVF outcomes. The
AMH levels in the pregnant and nonpregnant women did not
differ (Table 1) and two pregnancies were recorded in women
with negligible AMH levels (<1.14 pmol/L) supporting previ-
ous suggestions that AMH is not suitable to be used as a single
predictor in the pregnancy prospect assessment [7, 18, 19].
The important role of age in the pregnancy prospects was
confirmed in our study population too [7, 18]. The age cut-
off value of 37.5 years demonstrated the best performance for
the discrimination of the patients with diminished ovarian
reserve who will or will not become pregnant after assisted
conception.Thepatientswith lowAMHand≤37.5 years of age
had higher CPR then their older counterparts, 23.2% versus
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Figure 1: Comparison of area under the receiever operating char-
acteristics curve (AUC-ROC) of the multivariate model for clinical
pregnancy prediction combining DHEAS and female age (DHAES-
age model) and the univariate models based on age as continuous or
categorical variable. DHEAS-age = multivariate categorical model
usingDHEAS as categorical variable with cut-off value of 5.7 𝜇mol/L
and age as categorical variable with cut-off value of 37.5 years; age-
c = univariate model using age as categorical variable with cut-off
value of 37.5 years; age = univariate model using age as continuous
variable; 𝑃 value < 0.05 is considered statistically significant.
3.5% (𝑃 < 0.001) which also confirms recently reported
association between age and IVF outcomes within the given
AMH category [10].
Among all the other clinical and biochemical charac-
teristics tested, DHEAS was found to be the best single
predictor of clinical pregnancy in our study population.
DHEAS is a sulfated metabolite of DHEA which is involved
in ovarian steroidogenesis as a hormone precursor, and can
be partially metabolized into active androgens and estrogens
in peripheral tissues [20]. Levels of DHEA(S) decline linearly
and systematically with age [21, 22] and epidemiological
studies suggest that DHEA(S) may have beneficial effect on
age-related conditions [23]. According to the recent concept
of ovarian ageing, DHEA supplementation may beneficially
affect aging of ovarian environments and thus improve a
oocyte/embryo quality [24].
In this study, the overall predictive power of the DHEAS-
age model was significantly better in predicting pregnancy
compared to the model based on female age alone (Table 2).
However, DHEAS levels seem to be related to the chances
for pregnancy only in the <37.5 year age category. In this
age category, the differences in other baseline patient char-
acteristics between the two groups (Group 1 and Group
2) differing in the DHEAS levels were not observed, with
exception of T which could be attributed to the enhanced
androgenic conversion of the higher amount of DHEA
(Table 3). Together with the lack of differences in the number
of oocytes retrieved and embryos transferred in thesewomen,
the observed differences in CPR and implantation rate could
be explained by the possible influence of DHEA(S) on the
oocyte quality rather than quantity as recently proposed
[24].
The observed difference in CPRs between groups differ-
ing in theDHEAS levels within≥37.5 years age category failed
to reach the level of significance which could be attributed to
the small number of patients with higher DHEAS levels in
this age category (Table 3). However, similar CPR in patients
<37.5 years and DHEAS ≤ 5.7𝜇mol/L (Group 2) and patients
≥37.5 years and DHEAS ≤ 5.7𝜇mol/L (Group 4) suggests
that the potential effect of DHEAS deficiency on the oocyte
quality reduces the pregnancy chances in younger patients to
the level inherent to the older age categories (Table 3).
Our study results support outcomes of previous studies
suggesting the continuation of pursuit for the patient char-
acteristics potentially associated with IVF outcome success
and the need for development of themore accurate predictive
models that will refine patient counseling approach as the
accuracy of currently used predictors of pregnancy after IVF
is not optimal [4, 25].
If age-alone model for pregnancy prospects had been
applied at initial patient counseling and 37.5 years used as the
cut-off value for the pregnancy prediction, 53.5% (69/129) and
46.5% (60/129) of couples from our study population should
had been counseled as to have >20% and <5% chances for
pregnancy, respectively. Here, presented data suggest that the
information on the DHEAS level might be helpful in preg-
nancy prospects assessment prior to the first IVF treatment
with GnRH antagonist ovarian stimulation protocol at least
in women <37.5 years with low AMH. Patients <37.5 years
with higher DHEAS levels could, accordingly, be reassured as
having their chances for pregnancy similar to that of general
IVF population. On the other hand, patients with lower
DHEAS from the same age category could be counseled as
having their pregnancy prospects similar to that of patients’
≥37.5 years. Using this approach, 42% of patients could be
counseledmore accurately compared to the predictionmodel
that relies on the female age only.
The main limitation of this study is the small number
of patients that is mainly a consequence of the rigorous
inclusion criteria as only patients who underwent their first
IVF cycle and were treated with the same initial dose of
gonadotrophins in GnRH antagonist protocol of ovarian
stimulation were selected for the analysis. Further limitations
are the DHEAS cut-off specificity for the applied DHEAS
immunoassay and particular Croatian legislation setting
which both prevent universal application of here presented
counseling approach for expected poor responders.
In summary, the information on DHEAS levels could
improve clinician’s ability to counsel the couples more accu-
rately about the probabilities for successful IVF treatment
outcome in women with low AMH who were younger than
37.5 years. Further studies, prospectively addressing this
International Journal of Endocrinology 7
specific issue on the large patient population in different
settings are needed to evaluate these findings.
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